Search
forResearch 8 of 116
- High incidence of severe hand–foot syndrome during capecitabine–docetaxel combination chemotherapy
- [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].
- Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda®)
- Anlotinib or Bevacizumab Combined with Taxane/Capecitabine for the Second-Line or Subsequent Treatment of HER-2 Negative Metastatic Breast Cancer: A Retrospective Cohort Study
- Alopecia and Hair Damage Induced by Oncological Therapy
- Targeted Therapy– and Chemotherapy-Associated Skin Toxicities: Systematic Review and Meta-Analysis
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Reporting on Adverse Clinical Events
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →